Fortress Biotech, Inc.

NASDAQ:FBIO

Biotechnology

Healthcare
$1.89 -1.79%

-$0.06 today

Market cap
$63.03M
Beta
1.23
P/E (TTM)
0.7
EPS (TTM)
$4.05
52W Low $1.70High $4.53

Volume 0.41M

Average 0.43M

FBIO Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Fortress Biotech, Inc.NASDAQ: FBIO

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $16.43M fell 46.4% year over year, behind the -27.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 6.5% from the prior quarter. Over 3 fiscal years it compounded at -23.2% a year.

Context

  • Operating expenses amounted to 177.9% of revenue in FY2025, down 77.3 pp from a year earlier.
  • Operating expenses increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -46.4% toward the trailing-twelve-month pace of -27.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.43M+6.5% QoQ
Last fiscal yearDec 2025
$112.56M-23.5% YoY
LTMMar 2026
$98.5M-27.0% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-46.4%——
1 year-23.5%——
3-year CAGR-23.2%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
112.56M USD
Year-over-year change
-23.5%
4-year CAGR
-15.9%

Operating Expenses vs competitors

How FBIO compares with its peers on the latest reported figures

  • FBIO's LTM Mar 2026 operating expenses of $98.5M is the 4th highest of the 10 companies compared; the peer median is $60.34M.
  • Its year-over-year change of -27.0% is the lowest of 9, against a peer median of +1.6%.
  • Operating expenses amounts to 148.9% of revenue for FBIO, versus a peer median of 991.1%.
FBIO Competitors Peer median
Operating Expenses for FBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$217.43M +108.0%+24.1%85.1%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$137.15M -4.8%+21.4%1501.1%
IMUXImmunic, Inc.LTM Mar 2026$109.61M +8.6%-4.8%—
FBIOFortress Biotech, Inc.LTM Mar 2026$98.5M -27.0%-23.2%148.9%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$83.6M -5.5%+4.1%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$60.34M -23.7%-28.4%—
XBITXBiotech Inc.LTM Mar 2026$48.08M +6.4%+12.6%—
ADAGAdagene Inc.LTM Jun 2024$36.55M —-32.2%4480.0%
GANXGain Therapeutics, Inc.LTM Mar 2026$19.69M -3.2%+1.5%—
NTRBNutriband Inc.LTM Apr 2026$8.67M +23.7%+22.0%481.0%
Peer median (excluding FBIO) $60.34M+1.6%+4.1%991.1%

Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue68.79M75.74M84.51M57.68M63.26M
Cost of Revenue32.08M30.78M22.89M20.88M20.92M
Gross Profit36.71M44.97M61.62M36.8M42.34M
Gross Margin53.4%59.4%72.9%63.8%66.9%
Research & Development128.87M134.88M106.07M56.88M11.9M
Selling, General & Admin86.84M113.66M90.98M87.73M96.4M
Operating Expenses225.25M248.53M203.96M147.18M112.56M
Depreciation & Amortization6.79M9.35M6M4.46M4.66M
EBITDA(146.17M)(193.69M)(135.72M)(104.49M)(20.17M)
EBITDA Margin-212.5%-255.7%-160.6%-181.2%-31.9%
Operating Income(188.54M)(203.56M)(142.34M)(110.38M)(70.22M)
Operating Margin-274.1%-268.8%-168.4%-191.4%-111.0%
Interest Income649K1.4M3M2.68M2.49M
Interest Expense15.31M13.64M12.52M9.93M8.71M
Other Income / Expenses24.19M(9.9M)(11.29M)(10.16M)36.69M
Income Before Tax(164.35M)(213.46M)(153.63M)(120.54M)(33.54M)
Pre-Tax Margin-238.9%-281.8%-181.8%-209.0%-53.0%
Income Tax Expense473K449K521K312K(620K)
Net Income(64.7M)(86.58M)(60.64M)(46M)6.82M
Net Margin-94.1%-114.3%-71.7%-79.8%10.8%
EPS (Basic)(11.85)(14.55)(8.47)(2.69)(0.07)
EPS (Diluted)(11.85)(14.55)(8.47)(2.69)(0.07)
Weighted Avg Shares5.45M5.93M8.11M20.78M27.9M
Weighted Avg Shares (Diluted)5.45M5.93M8.11M20.78M279.02M

Fortress Biotech, Inc.

NASDAQ:FBIO

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.